Celularity Inc. (CELU)

3.0300 -0.1800 (-5.61%) At close: 04:00PM EDT

Celularity Inc.

170 Park Avenue
Florham Park, NJ 07932
United States
908 768 2170
https://www.celularity.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 225

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Robert Joseph Hariri M.D., Ph.D.	Founder, CEO & Chairman	1.24M	N/A	1959
Mr. David C. Beers C.F.A.	Chief Financial Officer	455.02k	N/A	1970
Mr. John R. Haines	Senior EVP, Global Manager & Chief Administrative Officer	503.56k	N/A	1958
Ramji Krishnan	Chief Technology Officer	N/A	N/A	N/A
Carlos Ramirez	SVP of Investor Relations	N/A	N/A	N/A
Mr. Kyle Harold Fletcher Esq.	Executive VP, General Counsel & Chief Compliance Officer	N/A	N/A	1985
Dr. Stephen A. Brigido D.P.M.	President of Degenerative Diseases	N/A	N/A	1976
Dr. Adrian Kilcoyne M.B.A., M.D., M.P.H.	Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs	N/A	N/A	1971
Sharmila Koppisetti M.D.	Senior Vice President of Clinical Dev. Immunology & Drug Safety	N/A	N/A	N/A
Mr. Tim Wilk	Senior Vice President of Technical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Corporate Governance

Celularity Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.